Bemcentinib combo posts 30% ORR in PD-L1-negative NSCLC

BerGenBio ASA (OSE:BGBIO) reported data from 10 evaluable previously treated patients with PD-L1-negative non-small cell lung cancer in the Phase II BGBC008 trial showing that bemcentinib (BGB324) plus Keytruda pembrolizumab led to a best overall response rate (ORR) of 30%. All three responders achieved partial responses, plus four patients achieved stable disease and three patients had progressive disease. The data were presented at the World Conference on Lung Cancer in Toronto.

In the Phase Ib KEYNOTE-001 trial, Keytruda as monotherapy led to an ORR of 9.9% in previously treated PD-L1-negative NSCLC patients...